Physician profile
Elham Jafroodi
NPI 1033473533
$12,719.56
in general payments reported to CMS, 2019-2025
16 companies · $674 in 2025
The $674 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,059 · 2022: $136 · 2023: $9,022 · 2024: $1,829 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,125 · Food and Beverage: $2,363 · Travel and Lodging: $1,864 · Honoraria: $875 · Consulting Fee: $280 · Education: $18.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,124.50 |
| Food and Beverage | $2,363.17 |
| Travel and Lodging | $1,864.18 |
| Honoraria | $875.00 |
| Consulting Fee | $280.00 |
| Education | $18.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $9,870.31 | 2023-2024 | Krazati |
| Genentech, INC. | $750.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $456.03 | 2024-2025 | Lynparza, Enhertu |
| Epizyme, INC. | $397.94 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $245.65 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $229.87 | 2023-2025 | Orgovyx |
| Edwards Lifesciences Corporation | $136.55 | 2025 | Sapien 3 Ultra Resilia |
| Argenx US, INC. | $115.14 | 2025 | Vyvgart |
| Sage Therapeutics, LLC | $106.67 | 2024 | |
| Hologic Sales and Service, LLC | $104.92 | 2024 | Aptima |
| Biogen, INC. | $94.38 | 2023 | |
| Amgen INC. | $85.22 | 2025 | Krystexxa |
| Biohaven Pharmaceuticals, INC. | $46.77 | 2021 | |
| Daiichi Sankyo INC. | $42.76 | 2025 | Enhertu |
| Glaxosmithkline, LLC. | $19.35 | 2023 | Ojjaara |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $18.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elham Jafroodi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.